Array Biopharma Inc.

Genentech, Inc.

Loxo Oncology, Inc.

Mike Welch

Gabrielle R Kolakowski

Adam Wade Cook

Tony P Tang

David A Moreno

Andrew T Metcalf

Charles Todd Eary

Weidong Liu

Stacey Spencer

Katelyn Chando

Sylvie Asselin

Zack Crane

Joseph P Lyssikatos

James F Blake

Jun Liang

Stephen T Schlachter

Brian Salvatore Safina

Ellen Ruth Laird

Rui Xu

Ian S Mitchell

George T Topalov

Dengming Xiao

Keith Lee Spencer

Nicholas C Kallan

Martin F Hentemann

Brad Newhouse

Josef R Bencsik

Jonas Grina

James M Graham

Josh Hansen

Alan G Olivero

In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.

Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrile

The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof.  Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Pyrimidyl cyclopentanes as AKT protein kinase inhibitors

The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. 

Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Imidazopyrazines as Raf inhibitor compounds

Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

RAF inhibitor compounds and methods

Growing community of inventors

Westminster, CO, United States of America

Mike Welch